Novartis gets European OK for biosimilar of Amgen's Enbrel

ZURICH (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news